Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis

Background: There is mounting evidence that current replacement regimens fail to restore health-related subjective health status fully in patients with adrenal insufficiency ( AI). Here we evaluated the subjective health status in primary and secondary AI and the effect of concomitant disease. Methods: In a cross-sectional study, all AI patients registered with the University Hospital Wuerzburg ( n = 148) or with the German Self- Help Network ( n = 200) were contacted by mail. Underlying diagnoses and comorbidities were verified by review of medical records. Patients were asked to complete three validated self-assessment questionnaires [Short Form 36 ( SF-36), Giessen Complaint List ( GBB-24), Hospital Anxiety and Depression Scale ( HADS)]. Results were compared to sex- and age-matched controls drawn from the questionnaire-specific reference cohorts. Results: We identified 348 patients, and 256 agreed to participate. Completed questionnaire sets were available from 210 patients [ primary AI ( n = 132), secondary AI ( n = 78)]. Seven of eight SF-36 dimensions, all five GBB-24 scales, and the HADS anxiety score reflected significant impairment of subjective health status in both AI cohorts ( all P <0.001). Even after exclusion of all patients with any concomitant disease, subjective health status remained significantly impaired in five SF-36 subscales and four GBB-24 subscales. Secondary AI patients were slightly more compromised than primary AI, significant with regard to two SF-36 scales ( P <0.05) and the HADS depression score ( P <0.001). A total of 18.3% of the AI patients were out of work, compared to 4.1% in the general population. Conclusion: Patients with AI on current standard replacement suffer from significantly impaired health-related subjective health status, irrespective of origin of disease or concomitant disease. Future studies will have to assess whether more physiological glucocorticoid replacement strategies in AI will ameliorate these impairments.